Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.
 

 

 

 

 

University of Pittsburgh Schools of the Health Sciences

​University Of Pittsburgh Awarded $7.7 Million For Dendritic Cell Research

PITTSBURGH, May 26, 1998 — Investigators at the University of Pittsburgh have received a $7.7 million, five-year award from the National Cancer Institute (NCI) to study how dendritic cells participate in generating immunity against cancer cells, inducing transplant tolerance, and modifying auto-immunity that results in diseases such as diabetes and the arthritic condition, scleroderma. The large grant involves five separate projects and four "core" research facilities that will enable investigators to engage in their studies.

"This funding provides us an unprecedented opportunity to expand our studies of dendritic cell biology and its importance in disease," said Michael T. Lotze, M.D., principal investigator on the grant; professor of surgery and of molecular genetics and biochemistry; and co-director of the University of Pittsburgh Cancer Institute’s (UPCI) Biological Therapeutics Program. Olivera Finn, Ph.D., professor of molecular genetics and biochemistry and of surgery and director of the UPCI’s Program in Immunology is the co-principal investigator on the grant.

"We have a unique gathering of internationally recognized investigators who are exploring dendritic cell-based therapies at a time when the isolation, culture and application of these cells to human disease have progressed significantly," added Dr. Lotze.

Dendritic cells are considered the pacemakers of the immune system, according to Dr. Lotze. These cells are the first to recognize and process antigens, proteins found on or within intruders such as viruses or bacteria. Dendritic cells, which traffic throughout the body, introduce these foreign antigens to other specialized cells of the immune system that assist in antibody production or kill the invaders directly.

Of five projects funded by this grant, one, led by Dr. Lotze and Lou Falo, M.D., is designed to elucidate key biological factors necessary for developing potent, dendritic cell-based vaccines against cancer. A second project, led by Dr. Lotze, Walter Storkus, Ph.D., and Andrew Amascato, Ph.D., is aimed at introducing antigenic substances to dendritic cells or genetically modify these cells so they produce growth factors (cytokines) that would increase their effectiveness against cancer. A third project, led by Olivera Finn, Ph.D., Pawel Ciborowski, Ph.D., and Dr. Amoscato, will focus on the development of dendritic cell-based vaccines for lung cancer. A fourth project, led by Penelope Morel, Ph.D., Angus Thomson, Ph.D., D.Sc., and Hideaki Tahara, Ph.D., will focus on the importance of dendritic cells in a mouse model of the autoimmune disease, diabetes. A fifth project, led by Timothy Wright, M.D. and Susan McCarthy, Ph.D., will focus on how dendritic cells stimulate auto-immunity in scleroderma.

UPCI administrators, along with researchers and physicians in UPCI’s Immunologic Monitoring and Diagnostic Laboratories, the Vector Core Facility, and the Biologic Imaging Center also will contribute to this large project.

One of 31 NCI-designated comprehensive cancer centers, the UPCI is a recognized leader in patient care and translational biomedical research. The University of Pittsburgh Medical Center houses the world’s largest liver transplant program, where surgeons perform more types of transplants than any other center, and where researchers engage in a wide range of basic and clinical research projects to improve transplantation.

 

 
 

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com